GET DAILY SIGNALSCerus (CERS) Delivers Breakeven Q3 Results with 10% Product Revenue Growth
Key Takeaways
- Cerus reported third quarter 2026 product revenue of $57.7 million, up 10% year over year, with total revenue of $64.0 million including government contracts.
- The company posted breakeven earnings per share of $0.00, beating the consensus estimate for a $0.01 loss.
- Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) reached $5.7 million, marking a tenth consecutive positive quarter.
- Management reaffirmed full-year 2026 product revenue guidance of $229 million to $231 million, including IFC sales of $23 million to $25 million.
- Cerus announced positive top-line results from its Phase 3 RedeS study of the INTERCEPT red blood cell system, while the European CE mark timeline for red cells moved to late 2027.
- For more detail, explore the ticker's Major News, Today's Price Move, Price Targets, and Forecast pages.
- Discover automated market insights by exploring Trending AI Robots.
Putting the Quarter in Context
Cerus Corporation focuses on protecting the global blood supply with its INTERCEPT Blood System, which helps reduce pathogens in platelets, plasma, and other components. These third-quarter figures matter because they show whether the company can maintain solid product growth while steadily improving profitability. Over recent periods, management has narrowed GAAP losses and produced consistent positive adjusted EBITDA, pointing to progress toward breakeven. Attention also centers on the move toward higher-margin IFC kit sales and the timing of regulatory steps for red blood cells and the INT200 device. This update serves as a useful checkpoint on commercial traction and the route to sustainable profits. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
Cerus reported third quarter 2026 product revenue of $57.7 million, a 10% increase from the prior-year period, supported by rising demand for IFC and INTERCEPT platelets in the United States along with EMEA placements of the next-generation INT200 illuminator. Total revenue, which included $6.3 million in government contract revenue, reached $64.0 million. North American product revenue grew 12%, while EMEA product revenue rose 5%, partly offset by foreign exchange headwinds of about 2%.
On the bottom line, the company delivered breakeven earnings per share of $0.00, ahead of the consensus estimate for a $0.01 loss. On a GAAP basis, Cerus recorded a net loss of roughly $0.55 million. Product gross margin stood at 52.4%, compared with 53.4% a year earlier but improved from 51.4% in the second quarter, aided by the shift of IFC sales to a kit-based model. IFC revenue climbed to $5.6 million from $3.9 million a year ago, with about 90% of IFC sales shipped in kit form.
Adjusted EBITDA rose to $5.7 million, the tenth straight positive quarter, and operating cash flow turned positive at $3.0 million. Management reaffirmed full-year 2026 product revenue guidance of $229 million to $231 million.
Market Reaction and Investor Sentiment
Sentiment before the report had already softened after a stretch of slowing product growth, and the initial market response showed a measured tone. Even with the earnings beat and positive RedeS data, shares eased in after-hours trading as investors balanced slower top-line trends against extended timelines for two key regulatory catalysts. The headline numbers looked solid—breakeven earnings versus an expected loss, reaffirmed guidance, and a real pipeline advance—yet the details underscored a slowdown from 24% growth in the first quarter to around 10% in the third. Slower EMEA expansion linked to geopolitical issues and deferred orders, plus the push of the European CE mark for red cells to late 2027, gave investors cause to stay cautious even as profitability and cash flow improved.
Forward Outlook and Key Factors to Monitor
Looking ahead, the focus will be on whether Cerus can turn its improving profitability into lasting bottom-line gains. The company kept its full-year product revenue outlook, which implies fourth-quarter product revenue of roughly $60 million to $62 million and points to more moderate growth as the year wraps up. Tracking whether North American platelet and IFC volumes continue to outpace the broader market remains central.
Regulatory timelines stand out as important variables. Management now anticipates the European CE mark for the INTERCEPT red blood cell system in late 2027, later than the earlier first-half 2027 expectation. Separately, the FDA has asked for additional data on the INT200 platelet device PMA application, so approval in the first half of 2027 is no longer certain. These steps represent meaningful longer-term revenue potential.
On the financial side, the balance sheet deserves attention. Cerus reported cash and investments of about $57.1 million against term debt and revolver borrowings, and it is refreshing its shelf registration, which keeps options open but also raises the possibility of dilution. Gross margin trends, the ongoing IFC kit conversion, and the path to GAAP profitability will stay in focus in coming quarters. From what I see, checking signals with Tickeron’s AI Trend Prediction Engine adds useful perspective on momentum.
AI Tools in My Research Process
When analyzing names like CERS, I often turn to Tickeron’s AI Screener for a quick way to compare fundamentals, technical patterns, and performance across the healthcare sector. It helps surface relevant data points efficiently without replacing deeper fundamental work.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CERS's Stochastic Oscillator is sitting in overbought zone for 7 days
The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CERS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
CERS broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CERS entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CERS's RSI Oscillator exited the oversold zone, 24 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on CERS as a result. In 80 of 103 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for CERS just turned positive on October 20, 2026. Looking at past instances where CERS's MACD turned positive, the stock continued to rise in 36 of 44 cases over the following month. The odds of a continued upward trend are 82%.
Following a +1.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where CERS advanced for three days, in 167 of 224 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.792) is normal, around the industry mean (4.209). P/E Ratio (-78.667) is within average values for comparable stocks, (1.433). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (2.219) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. CERS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CERS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of the INTERCEPT Blood System for platelets and plasma
Industry MedicalNursingServices
Advertisement